Shane Hebel

Lecturer on Law

Spring 2022


Shane Hebel is a Lecturer on Law at Harvard Law School, where he teaches the Negotiation Workshop. Shane is also the Director of New Product and Market Development for OraSure Technologies, where he focuses on developing and commercializing diagnostics to improve outcomes related to HIV and Hepatitis C, infectious diseases that most burden traditionally marginalized communities. Shane serves as a member of the Boston HIV Research Community Advisory Board and represents community interests in a number of ongoing HIV and COVID clinical trials.

Shane’s research focuses on improving health outcomes for traditionally marginalized and minoritized populations, including men who have sex with men, transgender people, people who inject drugs, people who engage in sex work, and people who intersect with the incarceration system with a focus on systems improvements and patient-provider interactions. His work has been featured in the Journal of AIDS and he has presented his work at venues including the United States Conference on HIV and AIDS, the International AIDS Society conference, and the Conference on Retroviruses and Opportunistic Infections, among others.

Shane’s prior experience includes helping to run an HIV diagnostics startup (acquired by OraSure Technologies), working at McKinsey & Co., where he focused on supporting clients within the healthcare sector, and consulting with the UNAIDS Human Rights and Law team. Shane has also served as a trainer for numerous negotiation courses and programs, including for the Harvard Negotiation Institute, INSEAD, Massachusetts General Hospital, and in-house trainings at McKinsey & Co and UNAIDS.

Shane is a graduate of Harvard Law School (JD, 2017), the Quantic School of Business and Technology (MBA, 2020), and York University (BBA, 2013). While at Harvard Law School, he was the co-Editor-in-Chief of the Harvard Law and Policy Review. He lives in Somerville, Massachusetts with his husband and spends his time volunteering as an online crisis counsellor and competing in marathons and triathlons.

Areas of Interest

Shane Hebel et. al., Brief Report: Discrepancies Between Self-Reported Adherence and a Biomarker of Adherence in Real-World Settings, 85 JAIDS 454 (2020)
Health Care
Health Law & Policy
Type: Article
Pre-exposure prophylaxis (PrEP) is only effective in preventing new HIV infections when taken consistently. In clinical practice, asking a patient about their adherence (self-report) is the predominant method of assessing adherence to PrEP. Although inexpensive and noninvasive, self-report is subject to social desirability and recall biases. Several clinical trials demonstrate a discrepancy between self-reported adherence and biomarker-based recent adherence. Less is known about the accuracy of self-report in real-world clinical settings. This brief report addresses this knowledge gap and describes the concordance between self-reported adherence and biomarker-based adherence in real-world clinical settings.
Lisa K. Dicker & Shane K. Hebel, The Litigators: Perceptions of Predictability, Definitions of a Good Outcome, and an Alternative to Mass Tort Trials, 48 U. Mem. L. Rev. 987 (2018)
Civil Practice & Procedure
Type: Article